Institut De Recherches Internationales Servier (i.r.i.s.)

This study tests a daily pill called vorasidenib in 10 teenagers (ages 12 to 17) with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how it affects growth and development, and whether it can…

This early-phase study looks at how a single dose of the drug vorasidenib is handled by the body in people with severe liver impairment compared to those with normal liver function. About 20 participants will take one pill and be monitored for up to 77 days with blood tests and h…